Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 45, Issue -, Pages 1-7Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.11.001
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R01CA157303]
- Augusta University Georgia Cancer Center
- Georgia Research Alliance (GRA)
- Grants-in-Aid for Scientific Research [16K20223] Funding Source: KAKEN
Ask authors/readers for more resources
Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available